BioSpace News Archive

CurvaFix, Inc. announced the launch of its smaller-diameter, 7.5mm CurvaFix® IM Implant, designed to simplify surgery and provide strong, stable fixation in small-boned patients.

Labcorp, a leading global life sciences company, announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials evaluating the safety and efficacy of ADX‑629, a novel, internally developed, investigational oral RASP modulator, for the treatment of minimal change disease and Sjögren-Larsson Syndrome.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2022 results and recent business performance.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2022 financial results and corporate update for Thursday, March 2, 2023.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) today announced that Company management will participate in a fireside chat at Citi’s 2023 Virtual Oncology Leadership Summit, on Thursday, February 23rd at 11:00 a.m. ET.

Pasithea Therapeutics Corp. announced that Prof. Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will receive the 2023 Pioneer in Medicine Award at the 20th Annual Gathering for the Cure on February 17 as part of the 20th Annual World Congress of SBMT.

Accuray Incorporated announced that data from the randomized, multicenter trial PACE-A indicates that stereotactic body radiation therapy, in comparison to surgery, better preserves urinary continence and sexual function in men with localized prostate cancer.

Assertio Holdings, Inc. announced that Dan Peisert, CEO, and Paul Schwichtenberg, CFO, will host investor meetings Thursday, February 23, 2023 as part of the virtual Third Annual Winter Wonderland Best Ideas Investor Conference.

ProPhase Labs, Inc. announced that its flagship diagnostic test, which is undergoing clinical validation as a laboratory developed test for esophageal cancer screening, was featured in International Journal of Molecular Science, volume 24, no. 4 edition.